Dr Reddy's Q4 profit jumps 76% to Rs 764 cr on higher sales in US, Europe; revenue up 10% at Rs 4,432 cr

Dr Reddy's said various initiatives have been undertaken to ensure that our manufacturing-related operations continue unabated enabling it to serve the patients.

Asian News International May 20, 2020 16:35:08 IST
Dr Reddy's Q4 profit jumps 76% to Rs 764 cr on higher sales in US, Europe; revenue up 10% at Rs 4,432 cr

Hyderabad: Dr Reddy's Laboratories Ltd on Wednesday reported a net profit of Rs 764 crore during the January to March quarter, up 76 percent from Rs 434 crore in the corresponding quarter of the previous financial year.

The company reported a revenue of Rs 4,432 crore, up 10 percent from the year-ago period. Its global generics segment clocked 20 percent year-on-year jump to Rs 3,640 crore.

The earnings before interest, taxes, depreciation and amortisation (EBITDA) came at Rs 1,001 crore while EBITDA margin was at 22.6 percent.

Dr Reddys Q4 profit jumps 76 to Rs 764 cr on higher sales in US Europe revenue up 10 at Rs 4432 cr

Representational image. News18

"FY 20 has been a very positive year for the company," said co-Chairman and Managing Director GV Prasad.

"Progress made during the year includes VAi status for CTO 6, healthy product pipeline build-up, productivity improvement and strong financial performance across our businesses."

Among the geographies, Europe's segment saw a jump of 80 percent in revenue while North America and emerging markets rose 21 percent and 15 percent respectively.

India segment rose 5 percent year-on-year.

Dr Reddy's said various initiatives have been undertaken to ensure that its manufacturing-related operations continue unabated enabling it to serve the patients.

A few products related to COVID-19 are under development.

The board of directors has recommended a final dividend of Rs 25 (500 percent) per equity share of Rs 5 face value for the financial year 2019-20.

During the quarter, Dr Reddy's acquired select divisions of Wockhardt Ltd's branded generics business in India and a few other international territories like Nepal, Sri Lanka, Bhutan and Maldives.

The deal comprising a portfolio of 62 brands in multiple therapy areas was done on a slump sale basis for a consideration of Rs 1,850 crore.

Updated Date:

also read

India records 12,213 COVID cases in 24 hours, crosses 10K mark for first time since late February
India

India records 12,213 COVID cases in 24 hours, crosses 10K mark for first time since late February

The Ministry of Health and Family Welfare (MoHFW) informed that 11 people died of coronavirus in the last 24 hours, increasing total casualties to 5,24,803

India logs 7,584 new COVID-19 cases, 24 deaths in last 24 hours
India

India logs 7,584 new COVID-19 cases, 24 deaths in last 24 hours

India has 36,267 active cases of COVID-19. Active cases increased by 3,769 in the last 24 hours and now comprise 0.08 per cent of the total cases

Mansukh Mandaviya stresses on vaccination, genome sequencing amid COVID-19 surge
Health

Mansukh Mandaviya stresses on vaccination, genome sequencing amid COVID-19 surge

The health minister chaired a meeting with key experts and officials on COVID-19 and vaccination situation in the country on Thursday